Transgenomic Inks Blue Cross and Blue Shield Contract | GenomeWeb

NEW YORK (GenomeWeb News) – Transgenomic said today that it has expanded a national contractual agreement with the Blue Cross and Blue Shield Association.

The Omaha, Neb.-based molecular diagnostics and pharmacogenomics services firm said in a filing with the US Securities and Exchange Commission that the new agreement has a term of five years. Under the contract, Blue Plans affiliates have access to "competitive pricing" for Transgenomic's tests and services.

The firm didn't provide any additional details of the contract.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.